Literature DB >> 27698506

Comparison of Time to Therapeutic aPTT in Patients Who Received Continuous Unfractionated Heparin After Implementation of Pharmacy-wide Intervention Alerts.

Duaa Alsulaiman, Katelyn Sylvester, Craig Stevens, Danielle Carter.   

Abstract

Background: For patients on continuous IV unfractionated heparin (UFH), failing to achieve a therapeutic aPTT by 24 hours can be associated with increased morbidity. A pharmacy clinical surveillance system (PCSS) subtherapeutic aPTT alert was implemented at our institution to improve achievement of therapeutic aPTT goals by 24 hours. Objective: The primary objective was the time to achieve the minimum goal aPTT before and after the alert implementation. The secondary objectives were to examine the percentage of patients who achieved the minimum goal aPTT by 24 hours and the number of dose changes to achieve the minimum goal aPTT.
Methods: A single-center retrospective study was conducted to include all adult inpatients receiving a continuous UFH infusion during a 3-month period prior to the implementation of a subtherapeutic aPTT alert and a 3-month period after implementation.
Results: 317 patients were included in the analysis. The average time to achieve the minimum goal aPTT was 21.8 hours prior to alert implementation and 15.4 hours after implementation (p = .002). The percent of patients who achieved the minimum goal aPTT by 24 hours was 65.7% prior to alert implementation and 82.4% after implementation (p = .035). The average number of dose changes necessary to achieve aPTT value to the minimum goal aPTT prior to alert implementation was 1.67 and 1. 98 after implementation (p = .68).
Conclusion: This analysis showed that implementation of a PCSS subtherapeutic aPTT alert for patients on continuous UFH infusions may ensure patients reach goal aPTT faster and facilitate a higher percent of patients who achieve the minimum goal aPTT by 24 hours.

Entities:  

Keywords:  aPTT; alert; heparin; monitoring; pharmacy clinical surveillance system

Year:  2016        PMID: 27698506      PMCID: PMC5030878          DOI: 10.1310/hpj5108-656

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  20 in total

Review 1.  Guide to anticoagulant therapy: Heparin : a statement for healthcare professionals from the American Heart Association.

Authors:  J Hirsh; S S Anand; J L Halperin; V Fuster
Journal:  Circulation       Date:  2001-06-19       Impact factor: 29.690

2.  Clinical information technologies and inpatient outcomes: a multiple hospital study.

Authors:  Ruben Amarasingham; Laura Plantinga; Marie Diener-West; Darrell J Gaskin; Neil R Powe
Journal:  Arch Intern Med       Date:  2009-01-26

3.  Nurse-driven intravenous heparin protocol: quality improvement initiative.

Authors:  Tanya D Williams; Katherine Sullivan; Christopher Lacey; Steve Adoryan; Brook Watts
Journal:  AACN Adv Crit Care       Date:  2010 Apr-Jun

4.  An evaluation of empiric vs. nomogram-based dosing of heparin in an intensive care unit.

Authors:  G Brown; P Dodek
Journal:  Crit Care Med       Date:  1997-09       Impact factor: 7.598

5.  A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time.

Authors:  D Basu; A Gallus; J Hirsh; J Cade
Journal:  N Engl J Med       Date:  1972-08-17       Impact factor: 91.245

6.  Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis.

Authors:  R D Hull; G E Raskob; J Hirsh; R M Jay; J R Leclerc; W H Geerts; D Rosenbloom; D L Sackett; C Anderson; L Harrison
Journal:  N Engl J Med       Date:  1986-10-30       Impact factor: 91.245

Review 7.  Heparin therapy for venous thrombosis and pulmonary embolism.

Authors:  G E Raskob; C J Carter; R D Hull
Journal:  Blood Rev       Date:  1988-12       Impact factor: 8.250

8.  Impact of a clinical decision support system on pharmacy clinical interventions, documentation efforts, and costs.

Authors:  Stacy Calloway; Hameed A Akilo; Kyle Bierman
Journal:  Hosp Pharm       Date:  2013-10

9.  [Intravenous thrombolysis in myocardial infarction. Influence of the quality of the anticoagulation on the early recurrence rate of angina or infarction].

Authors:  J F Camilleri; J L Bonnet; J L Bouvier; G Levy; P Djiane; M Bory; A Serradimigni
Journal:  Arch Mal Coeur Vaiss       Date:  1988-09

10.  Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction.

Authors:  A G Turpie; J G Robinson; D J Doyle; A S Mulji; G J Mishkel; B J Sealey; J A Cairns; L Skingley; J Hirsh; M Gent
Journal:  N Engl J Med       Date:  1989-02-09       Impact factor: 91.245

View more
  1 in total

1.  Evaluation of Antifactor-Xa Heparin Assay and Activated Partial Thromboplastin Time Values in Patients on Therapeutic Continuous Infusion Unfractionated Heparin Therapy.

Authors:  Kevin McLaughlin; Jessica Rimsans; Katelyn W Sylvester; John Fanikos; David M Dorfman; Patricia Senna; Jean M Connors; Samuel Z Goldhaber
Journal:  Clin Appl Thromb Hemost       Date:  2019 Jan-Dec       Impact factor: 2.389

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.